A phase 1, randomised, double-blind, placebo-controlled, single ascending dose and multiple ascending dose study to evaluate the safety, tolerability, and pharmacokinetics in healthy adult subjects after subcutaneous injection of TISA-818-Inj-5mg/mL.

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506912-41-00

Acronym

TISA-818-22101

Enrollment

Registered

2023-11-27

Start date

2024-01-09

Completion date

2024-10-16

Last updated

2023-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic pulmonary fibrosis

None listed

Sex/Gender

All

Age

18 Years to 64 Years

Sweden

None listed

Source: EU CTIS · Data processed: Feb 4, 2026